Background Circulating tumour cell (CTC)–derived organoids have the potential to provide
a powerful tool for personalised cancer therapy but are restrained by low CTC numbers …

It was previously shown in the PC-295 xenograft that the number of chromogranin A (CgA)-positive
neuroendocrine (NE) cells increased after androgen withdrawal. NE cells did not …

… Lolkema a , John WM Martens a , Wytske M. van Weerden f , Guido W. Jenster f , John A.
Foekens a , … van Weerden has received research funding from Janssen, Sanofi, Millenium, and …

Recently, a unique fusion between the prostate-specific, androgen-regulated TMPRSS2
gene and the ETS genes ERG, ETV1, or ETV4 has been described in clinical prostate cancer. …

The present work focused on the potential involvement of selective adaptations of the
androgen receptor pathway in the initiation and progression of prostate cancer. We defined the …

Introduction Treatment options for patients with metastatic castration-resistant prostate cancer
(mCRPC) have expanded in recent years with the introduction of cabazitaxel, abiraterone …

Recent developments and improvements of multimodal imaging methods for use in animal
research have substantially strengthened the options of in vivo visualization of cancer-related …

Androgen-deprivation therapy for prostate cancer (PC) eventually leads to castration-resistant
PC (CRPC). Intratumoral androgen production might contribute to tumor progression …

… Wytske M. van Weerden has received research funding from Sanofi, Janssen, and Millennium.
Robert J. van Soest has received research funding and speakers honoraria from Sanofi. …

BACKGROUND Our understanding of the mechanisms of (progressive) growth of prostatic
cancer has been largely obtained through the study of experimental animal models. To be …